AZ9482, a potent and selective PARP inhibitor featuring an amide linkage to a 2-piperazinyl-3-cyano-pyridine.

Azaperone acts as a dopamine antagonist but also has some antihistaminic and anticholinergic properties. Azaperone is a pyridinylpiperazine and butyrophenone neuroleptic drug with sedative and antiemetic effects, which is used mainly as a tranquilizer in

Azatadine dimaleate is an histamine and cholinergic inhibitor with IC50 of 6.5 nM and 10 nM, respectively.

AZD 0424 is an orally bioavailable small molecule tyrosine kinase inhibitor of Abl and Src kinase with potential antineoplastic activity..

AZD 1678 is a potent, selective orally bioavailable CCR4 receptor antagonist with pIC50 of 8.6 for hCCR4, pIC50 of 9.0 for rCCR4.

AZD 3043 (THRX-918661) is a positive allosteric modulator of the GABAA receptor in vitro and a sedative/hypnotic agent in vivo, potentiates GABAA receptor-mediated chloride currents with EC50 of 36 uM.

AZD 3264 is an IkB-kinase IKK2 Inhibitor, IKK2 has been identified as one of the novel pathways to treat inflammatory conditions such as asthma, chronic pulmonary obstructive disorder (COPD) and rheumatoid arthritis.

AZD 4205 (AZD4205) is a potent, selective JAK1 inhibitor IC50 of 73 nM and Ki of 2.8 nM, shows high selectivity against JAK2 and JAK3 with IC50 of 13,233 nM and >30,000 nM respectively; shows potent inhibition of p-STAT3 in a cell based assay of JAK1 activity with an IC50 of 128 nM and excellent selectivity across the kinome; reduces residual disease and prolongs the benefit of Osimertinib in lung cancer patients with EGFR activating mutations both in vitro and in vivo.

AZD 6610 is a dual peroxisome proliferator-activated receptor (PPAR) α/γ agonist for treatment of diabetes mellitus..

AZD 7009 is a novel antiarrhythmic agent that inhibits the late sodium current in CHO K1 cells expressing hNav1.5 with IC50 of 11 uM.

AZD-0156 is an orally bioavailable ataxia telangiectasia mutated (ATM) kinase inhibitor, with potential chemo-/radio-sensitizing and antineoplastic activities.

AZD0284 is an inverse agonist of the nuclear receptor RORγ. In development for the treatment of plaque psoriasis vulgaris and respiratory tract disorders.

AZD-0364 is a potent and selective ERK2 inhibitor extracted from patent WO2017080979A1, compound example 18, has an IC50 of 0.6 nM.

AZD-0837 is a novel oral anticoagulant that after bioconversion to its active form is a potent and reversible thrombin inhibitor, has been investigated in phase II studies for prevention of stroke and systemic embolic events in patients with atrial fibril

AZD-1092 (GKA-80) is a potent Glucokinase (GK) activator with EC50 of 30 nM.

AZD-1305 is a novel antiarrhythmic agent that predominantly blocks the rapid component of IKr, the L-type calcium current, and the inward sodium current in mammalian cells and ventricular cardiomyocytes.

AZD2014 is a novel mTOR inhibitor with IC50 of 2.8 nM; highly selective against multiple PI3K isoforms (α/β/γ/δ).

AZD-26 is an inhibitor of AKT. AZD-26 inhibits the phosphorylation of Thr308 on AKT in BT474 cells with an IC50 of 422 nM.

AZD2716(AZD-2716) is a novel potent, selective, orally bioavailable sPLA2 inhibitor with excellent plasma sPLA2 inhibition (IC50=0.1 nM).

AZD2906 is a selective glucocorticoid receptor (GR) agonist, with IC50s of 2.2, 0.3, 41.6 and 7.5 nM at GR in human, rat PBMC and human, rat whole blood, respectively. AZD2906 increases micronucleated immature erythrocytes (MIE) in the bone marrow of rats

AZD-3161 is a potent and selective sodium channel Nav1.7 blocker for treatment of nociceptive pain. .

AZD3229 Tosylate is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors.

AZD3293 is a potent and selective orally active, brain-permeable BACE1 inhibitor,currently in development as a potential treatment for early Alzheimer’s disease.

AZD3514 is a potent and oral androgen receptor with Ki of 2.2 μM and has ability of reducing AR protein expression.

AZD-3988 is a potent and selective diacylglycerol acyltransferase (DGAT-1) inhibitor (IC50 = 0.6 nM).

AZD4017 is a potent, selective, and orally bioavailable human 11β-HSD1 with IC50 of 7 nM, shows no significant activity against 11β-HSD1 and 17β-HSD1, 17β-HSD3 (IC50>30 uM).

AZD4320 is a BH3 mimetic and dual Bcl-2/Bcl-XL inhibitor with IC50 of <1 nM.

AZD4573 is a CDK9 inhibitor with an IC50 of <3 nM extracted from patent US 20160376287 A1, example 14.

AZD-4818 is a highly potent, selective CCR1 antagonist with pIC50 of 8.6, inhibits chemotaxia of human monocytes to MIP-1α in a concentration-dependent manner.

AZD-5069 is a potent and selective CXCR2 antagonist with the potential to inhibit neutrophil migration into the airways in patients with COPD.

AZD5153 6-Hydroxy-2-naphthoic acid is the 6-Hydroxy-2-naphthoic acid of AZD5153. AZD5153 is a potent, selective, and orally available BET/BRD4 bromodomain inhibitor; disrupts BRD4 with an IC50 of 1.7 nM.

AZD5153 is a potent bivalent triazolopyridazine based Bromodomain and Extraterminal (BET) Inhibitor.

AZD-5248 is a potent, selective, first generation, oral inhibitor of dipeptidyl peptidase 1 (DPP1)..

AZD5576(AZD 5576) is a potent, highly selective, and orally bioavailable inhibitor of CDK9 with IC50 of < 5 nM, decreases phosphorylation of Ser2-RNAPII in cells with an IC50 of 96 nM.

AZD-5597 is potent CDK inhibitor with in vitro anti-proliferative effects against a range of cancer cell lines.

AZD5718 (AZD-5718, AZD 5718) is a novel potent 5-lipoxygenase activating protein (FLAP) inhibitor with binding IC50 of 6.3 nM; exhibits LTB4 inhibition in human whole blood assays with IC50 of 39 nM; reduce the production of pro-inflammatory and vasoactive leukotrienes both in vitro and in vivo.

AZD-5718 is an orally available small molecule, 5-lipoxygenase activating protein (FLAP) inhibitor..

AZD5904 (AZD-5904) is a potent, selective irreversible, orally bioavailable myeloperoxidase (MPO) inhibitor with IC50 of 140 nM, similar potency in mouse and rat.

AZD6088 (AZD-6088) is a potent and selective, orally bioavailable partial agonist of the M1 muscarinic receptor, reduces heat hyperalgesia in SNL rats with an EC50 of 46.6 nM..

AZD-7325 is a potent, α2/3 functionally selective, partial GABAA receptor modulator with pKi of 9.51.

AZD7507 (AZD-7507) is a potent, selective, orally available CSF-1R (c-FMS) with IC50 of 32 nM.

AZD-7594 (AZ-13189620) is a potent, nonsteroidal, selective glucocorticoid receptor modulator (SGRM) with binding IC50 of 0.9 nM, shows no affinity for AR, PR, MR and ERα/β.

AZD-7986(Brensocatib) is a highly potent, reversible, and selective DPP1 inhibitor with enzyme and cell pIC50 of 8.4.

AZD-8165 is a potent, selective and oral thrombin inhibitor for treatment of thrombosis..

AZD-8309 (AZD8309) is a potent and orally bioavailable CXCR2 antagonist that has been proposed to regulate the transmigration of neutrophils.

AZD8329 is a potent, selective 11β-HSD1 inhibitor with IC50 of 9 nM, displays excellent selectivity versus relatedd 11β-HSD2, 17β-HSD1 and 17β-HSD3 (IC50>30 uM).

AZD8330(ARRY-424704; ARRY-704) is a novel, selective, non-ATP competitive MEK 1/2 inhibitor with IC50 of 7 nM.

AZD8529 is a novel potent, selective mGluR2 positive allosteric modulator with EC50 of 195 nM, does not produce any positive allosteric modulator responses for mGluR1 and 3-8 subtypes.

AZD8529 is a novel potent, selective mGluR2 positive allosteric modulator with EC50 of 195 nM, does not produce any positive allosteric modulator responses for mGluR1 and 3-8 subtypes.

AZD8797 is an allosteric non-competitive modulator of the human CX3CR1 receptor; antagonizes CX3CL1 with IC50 values of 6 and 300 nM in B-lymphocyte cell line and human whole blood, respectively.

AZD9056 is a selective orally active inhibitor of P2X7 which plays a significant role in inflammation and pain-causing diseases.

AZD-9362 is dual IGF-IR/InsR inhibitor.

AZD-9567 (AZD9567) is a potent, selective, non-steroidal and orally available selective glucocorticoid receptor modulator (SGRM) for treatment of rheumatoid arthritis..

AZD-9567 (AZD9567) is a potent, selective, non-steroidal and orally available selective glucocorticoid receptor modulator (SGRM) for treatment of rheumatoid arthritis..

AZD-9819 is an inhibitor of human neutrophil elastase for potential treatment of chronic obstructive pulmonary disease..

AZD9977 is a first-in-class, potent, selective, mineralocorticoid receptor (MR) modulator with IC50 of 0.37. 0.08 and 0.08 uM for human, mouse and rat MR, respectively.

Azelaic acid is an organic compound produced by the ozonolysis of oleic acid and possesses antibacterial, keratolytic, comedolytic, and anti-oxidant activity.

Azetidine-2-carboxylic acid is a non proteinogenic amino acid homologue of proline. Found in common beets. Azetidine-2-carboxylic acid can be misincorporated into proteins in place of proline in many species, including humans. Toxic and teratogenic agent.

Azilsartan medoxomil is an angiotensin II receptor antagonist indicated for the treatment of mild to moderate essential hypertension.

Azimilide 2Hcl(NE-10064 2Hcl) is a class III antiarrhythmic compound, inhibits I(Ks) and I(Kr) in guinea-pig cardiac myocytes and I(Ks) (minK) channels expressed in Xenopus oocytes.

Azocosterol is a potential avian reproductive inhibitor.

Azosemide (Azosemidum) is a potent Na-K-Cl Cotransporter NKCC1 with IC50 of 0.246 and 0.197 uM for hNKCC1A and NKCC1B, being about 4-times more potent than bumetanide.

AZSMO-23 (AZSMO 23, AZSMO23) is a potent hERG potassium channel (Kv11.1) activator that activates WT hERG pre-pulse and tail current with EC50 of 28.6 and 11.2 μM respectively.

Azvudine (RO 0622) is a potent HCV NS5B RNA polymerase inhibitor, inhibits HCV replication in the replicon system with IC50 of 24 nM; inhibits RNA synthesis by HCV polymerases from either HCV genotypes 1a and 1b or containing S96T or S282T point mutations (IC50=10-100 nM).

Aβ polymerization stimulator O4 is an orcein-related small molecule can drive polymerization of amyloid-β (Aβ).

B I09 is an IRE-1 RNase inhibitor, with an IC50 of 1230 nM.

B591 (B-591) is a potent, specific pan-PI3K inhibitor with IC50 of 1.3/0.36/1.1/1.58 uM for PI3Kα/β/γ/δ, respectively.

BAA473 (BAA-473) is a bile acid analogue that functions as the first small molecule activator of the Pyrin inflammasome, induces secretion of IL18 in LPS-primed PBMCs.

BACE1-IN-2 is a 1,4-Oxazine β-Secretase 1 (BACE1) inhibitor with an IC50 of 22 nM.

Bafilomycin A1 is a vacuolar H+-ATPase inhibitor with IC50 of 0.44 nM.

BAL30072 is a monocyclic beta-lactam antibiotic that shows potent activity against MDR Pseudomonas aeruginosa and Acinetobacter sp. Isolates with MIC90 of 8 and 4 ug/ml.

Balamapimod (MKI-833) is an orally active, reversible Ras/Raf/MEK inhibitor developed for antineoplastic potential..

Balapiravir (R1626, Ro 4588161) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479).

Balovaptan (RG7314, RG-7314) is a potent, selective vasopressin-1 receptor antagonist..

Baloxavir acid (S-033447) is an anti-influenza compound that potently and selectively inhibits the cap-dependent endonuclease within the polymerase PA subunit of influenza A and B viruses.

Balsalazide is an anti-inflammatory compound used in the treatment of Inflammatory Bowel Disease.

Bamaquimast is an inhibitor of proton pump extracted from patent US2005165041, example 138.

BAR501 is a potent and selective agonist of GPBAR1 with an EC50 of 1 μM.

BAR502 is a dual FXR and GPBAR1 agonist with IC50 values of 2 μM and 0.4 μM, respectively.

Barbadin is a small molecule that selectively inhibits the β-arrestin/β2-adaptin interaction (IC50=19.1/15.6 uM for β-arrestin1/2) without effect on the formation of receptor/β-arrestin complexes.

Bardoxolone methyl (also known as “RTA 402” and “CDDO-methyl ester”) is an orally-available first-in-class synthetic triterpenoid belonging to the antioxidant inflammation modulator (AIM) class.

Baricitinib phosphate(INCB 028050; LY 3009104) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2,showed potent activity against COVID-19(SARS-COV-2).

Batimastat was used to study the role of MMP in proteolytic release of EGF in human follicular thyroid carcinoma cell line FTC-133.

BAY 1024767 (BAY1024767) is a higly potent antagonist of androgen receptor (AR) wild-type (IC50=46 nM) and mutant forms located in the AR ligand-binding domain (LBD).

BAY 1082439 is a highly selective and balanced PI3Kα/β inhibitor demonstrated potent activity in tumors with activated PI3Kα and loss-of-function of PTEN.

BAY 1143269 is a potent, selective, orally bioavailable inhibitor of MNK1 with enzyme IC50 of 40 nM at 2 mM ATP.

BAY 1143572 is a highly selective, potent and orally available inhibitor of PTEFb/CDK9; inhibits the proliferation of AML cell lines with a median IC50 of 385 nM.

BAY 1238097 is a novel BET bromodomain inhibitor with IC50 of 50 nM, inhibits the interaction between BRD4, BRD3 or BRD2 and H4 with IC50 values of 63 nM, 609 nM and 2430 nM in the NanoBRET assay.

BAY 2402234 (BAY2402234) is a novel potent, selective, orally bioavailable DHODH inhibitor with IC50 of 1.2 nM (human full-length DHODH).

Activator of soluble guanylyl cyclase (sGC); acts at a nitric oxide (NO)-independent regulatory site in the sGC α1 subunit. Inhibits platelet aggregation (IC50 = 36 nM) and phenylephrine-induced contractions of rabbit aorta (IC50 = 0.30 μM). Also reduces vascular smooth muscle growth through cAMP- and cGMP-dependent PKA and PKG pathways.. For the detailed information of BAY 41-2272, the solubility of BAY 41-2272 in water, the solubility of BAY 41-2272 in DMSO, the solubility of BAY 41-2272 in PBS buffer, the animal experiment (test) of BAY 41-2272, the cell expriment (test) of BAY 41-2272, the in vivo, in vitro and clinical trial test of BAY 41-2272, the EC50, IC50,and affinity,of BAY 41-2272, Please contact DC Chemicals.

BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC50 of 53 nM.

Bay 41-4109 less active enantiomer shows less activity than Bay 41-4109. BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC50 of 53 nM.

BAY 41-8543 is an NO-independent sGC (soluble guanylyl cyclase) stimulator, inhibits collagen-mediated aggregation in washed human platelets (IC50=90 nM).

BAY 57-1293 represents a new class of potent inhibitors of herpes simplex virus (HSV) that target the virus helicase primase complex.

BAY 60-2770 is an NO-independent activator of sGC (soluble guanylyl cyclase) with EC50 of 5.4 nM.

BAY 60-6583 (BAY606583) is a potent, selective adenosine A2B receptor agonist with EC50 of 2.83 nM (murine A2BR).

Bay 60-7550 is a potent PDE2 inhibitor with IC50 values of 2.0 nM (bovine) and 4.7 nM (human); 50-fold more selective for PDE2 compared to PDE1 and greater than 100-fold selective compared to PDE5, PDE3B, PDE4B, PDE7B, PDE8A, PDE9A, PDE10A, and PDE11A.

BAY 61-3606 is a potent, ATP-competitive, reversible, and highly selective inhibitor of Syk tyrosine kinase with Ki of 7.5 nM, displays no inhibitory effect against Btk, Fyn, Itk, Lyn, and Src.

BAY 85-8501 (BAY85-8501) is a potent, selective human neutrophil elastase (HNE) inhibitor with IC50 of 65 pM.

BAY1125976 is a selective allosteric Akt1/2 inhibitor; inhibits Akt1 and Akt2 activity with IC50 values of 5.2 nM and 18 nM at 10 μM ATP, respectively.

BAY-1316957 (BAY 1316957) is a highly potent, selective, orally available human prostaglandin E2 receptor subtype 4 (hEP4-R) antagonist with IC50 of 15.3 nM.

BAY-1436032 (BAY1436032) is a potent, selective, orally available inhibitor of pan-mutant IDH1 with IC50 of 15 nM for both IDH1 R132H and R132C, respectively.

BAY-1816032 (BAY1816032) is a highly potent, selective, orally active BUB1 mitotic checkpoint serine/threonine kinase with IC50 of 7 nM, displays excellent selectivity on a panel of 395 kinases.

BAY-293 racemate (BAY293 racemate) is a potent SOS1 inhibitor that disrupts the KRAS-SOS1 interaction with IC50 of 50 nM, the R-enantiomer (BAY-293) is the active form with IC50 of 21 nM, while the BAY-293 is less active (IC50=2,340 nM)..

BAY-320 (BAY320) is a potent, selective, ATP-competitive inhibitor of Bub1 kinase with IC50 of 680 nM.

BAY-3827 (BAY3827) is a potent, selective inhibitor of AMPK as tool compound to evaluate the therapeutic potential of AMPK inhibition in MYC-dependent tumors; strongly inhibits Acetyl-CoA carboxylase (ACC) phosphorylation in COLO 320DM and IMR-32 cells, but fails to inhibit the proliferation of cells with dysregulated c-MYC or N-MYC.

BAY-386 (BAY386) is a potent, specific and reversible PAR-1 antagonist with IC50 of 10 nM (HEK cell) and binding IC50 of 56 nM, without affinity for PAR-4 (IC50>10 uM).

BAY-524 (BAY524) is a potent, selective, ATP-competitive inhibitor of Bub1 kinase with IC50 of 450 nM.

BAY-678 racemate is a chemical probe candidate for Human Neutrophil Elastase (HNE).

BAY-707 is a highly potent, selective and substrate-competitive inhibitor of MTH1 (NUDT1) with IC50 of 2.3 nM.

BAY-7598 (BAY7598) is a potent, selective MMP12 inhibitor..

BAY-826 (BAY826) is a novel selective, highly potent, orally available TIE-2 inhibitor (dissociation constant=1.6 nM).

BAY-958 (BAY958, LDC526) is a potent, selective PTEFb/CDK9 inhibitor with IC50 of 5 nM against CDK9/CyclinT1.

Bayer-18 is a selective TYK2 inhibitor, with an IC50 of 18.7nM on TYK2 as measured by TYK2 HTRF assays.

BAZ2-ICR is a selective BAZ2 bromodomain inhibitor (Kd values are 109 and 170 nM for BAZ2A and BAZ2B respectively).

BB-Cl-Amidine is a peptidylarginine deminase (PAD) inhibitor.

BBT594 (NVP-BBT594), is potent and selective inhibitor of RET and JAK2.

BC-1215 (BC1215) is a highly unique, selective E3 ligase F box component Fbxo3 inhibitor with IL1β IC50 of 0.9 ug/mL.

BC-1485 is a first-in-class, small molecule inhibitor of FIEL1 (Fibrosis-inducing E3 ligase 1) that exhibits potent activity toward disrupting FIEL1-directed PIAS4 ubiquitination.

BC-21 (NSC 109268) is a novel small molecule inhibitor that effectively inhibits the β-catenin/Tcf4 interaction with Ki of 6.55 uM.

BC-23 (NSC 45382) is a novel inhibitor of β-catenin/Tcf4 interaction with IC50 of 1.7 uM.

BCI-137 is a chemical compound able to compete with Argonaute 2 miRNAs binding, binds to Ago2 with Kd of 126 uM.

BCL6 inhibitor 14 is a potent BCL-6 inhibitor with FRET IC50 of 63 nM..

BCL6 PROTAC 15 is a novel B-cell lymphoma 6 (BCL6) PROTAC, significantly degrade BCL6 in a number of DLBCL cell lines, but neither BCL6 inhibition nor degradation selectively induces marked phenotypic response.

BCL6-IN-8 (BCL6-i) is a potent, irreversible and cell-active BCL6 inhibitor with inact/KI value of 1.9 × 104 M-1 s-1, targets Cys53 located at the protein-protein interaction interface.

BCM-599 is an efficient HBV capsid assembly inhibitor with in vitro IC50 of 13 uM, shows synergistic inhibitory effects on decreasing viral concentration combined with lamivudine in vivo..

BCX-1470 (BCX1470) is a serine protease inhibitor that inhibits the esterolytic activity of factor D (IC50=96 nM) and C1s (IC50=1.6 nM).

BD-1047 is a potent, selecitve Sigma 1 receptor (σ1) antagonist with Ki of 0.93 nM.

BDA-366 is a Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.

BDCRB (GW 275175) is a potent and selective inhibitor of human CMV replication by blocking the processing and maturation of viral DNA..

BDP8900 (BDP-8900) is a highly potent and selective Myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with IC50 of 43 nM (MRCKβ), >100-fold selectivity over related ROCK1 or ROCK2.

BDP9066 (BDP-9066) is a highly potent and selective Myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with IC50 of 43 nM, >100-fold selectivity over related ROCK1 or ROCK2.

BDP-NAC is a novel persulfide donor that shows selectivity towards H2 O2 over other potential oxidative or nucleophilic triggers, resulting in the sustained release of the persulfide of N-acetyl cysteine (NAC).

BDT001 is a first-in-class, non-competitive FLT3 negative allosteric modulator, effectively prevents extracellular cytokine FL binding to FLT3 with IC50 of 11 uM.

Beauvericin is a cyclic hexadepsipeptide with antibiotic and insecticidal effects, shows activity against Gram-positive bacteria and mycobacteria, and is also capable of inducing programmed cell death in mammals..

Becampanel (AMP 397) potent, competitive antagonist of the AMPA receptor (AMPAR) with IC50 of 11 nM.

Befiradol (F13640, NLX 112) is a highly potent, selective 5-HT1A receptor agonist with Ki of 2.7 nM.

Befiradol hydrochloride is a selective 5-HT1A receptor agonist.

Begacestat (GSI-953) is a selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase (IC50Aβ40=15 nM) for the treatment of Alzheimer's disease.

Beloranib is being studied as a first-in-class obesity therapy that demonstrates a unique mechanism of action through methionine aminopeptidase 2 (MetAP2 ) inhibition.

Belvarafenib is a potent and pan RAF (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC50s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAFv600E and C-RAF respectively.

Bemesetron (MDL 72222) is a selective 5-HT3 receptor antagonist with an IC50 of 0.33 nM. Neuroprotective effect.

Bendamustine HCL (Ribomustin, Treanda, SDX-105) is a DNA-damaging agent with IC50 of 50 μM.

Benfluralin is a kind of herbicide and an agrochemical which can be used as a pre-emergence herbicide used for the control of grass and other weeds in a range of food and non-food crops.

Benzamidine is an inhibitor of serine proteases with Ki values of 35, 350, and 220 µM for trypsin, plasmin, and thrombin, respectively.

Benzamil hydrochloride is a specific and potent sodium channel (ENaC) blocker.

Benzarone (NSC 82134) is a small molecule inhibitor of Eyes Absen (EYA) protein tyrosine phosphatase activity (IC50=17 uM, EYA3), exhibits selectivity for EYA over PTP1B.

Benzenesulfonamide ia an inhibitor of carbonic anhydrases

Benznidazole (Ro 07-1051) is an antiparasitic medication, with an IC50 of 20.35 μM for Colombian T. cruzi strains, and has been used in the treatment of Chagas disease.

Benzocaine hydrochloride is a surface anesthetic that acts by preventing transmission of impulses along nerve fibers and at nerve endings.

Benzyl alcohol is an aromatic alcohol; a colorless liquid with a mild pleasant aromatic odor.

Benzylcetyldimethylammonium chloride hydrate is a chemical.

Bephenium hydroxynaphthoate is an anthelmintic compound that acts as an activiator of nematode B-type nAChR, is used in the treatment of hookworm infections and ascariasis..

Bephenium is an anthelmintic compound that acts as an activiator of nematode B-type nAChR, is used in the treatment of hookworm infections and ascariasis..

Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor.

Berotralstat is a potent human plasma kallikrein inhibitor.

Besifovir (PMCDG Dipivoxil, NA-380, LB-80380) is a potent, selective, orally available anti-HBV agent, the prodrug of PMCDG (EC50=4 uM)..

BET inhibitor CF53 is a highly potent, orally active inhibitor of bromodomain and extra-terminal (BET) with Ki of <1 nM (BRD4 BD1).

EIDD-1931 (β-d-N4-Hydroxycytidine, NHC) inhibits both murine hepatitis virus (MHV) (EC50 of 0.17 μM) and Middle East respiratory syndrome CoV (MERS-CoV) (EC50 of 0.56 μM) with minimal cytotoxicity. It also inhibits SARS-CoV-2 and multiple 2 endemic, epide

Betahistine is a strong affinity histamine H3 receptor antagonist and weak affinity agonist of histamine H1 receptors.

Betanin has potent antioxidant and anti-inflammatory effect, that could inhibit peroxynitrite (ONOO-), with an IC50 of 19.2 μM. Betanin is a red glycoside obtained from beets that can be used as colorant.

BET-BAY 002 is a potent BET inhibitor; shows efficacy in a multiple myeloma model.

BETd-260 (ZBC260, BETd260) is a novel PROTAC BET degrader that tether HJB97 to a ligand for the E3 ubiquitin ligase VHL.

BETd-260 trifluoroacetate (ZBC260, BETd 260 TFA) is a novel PROTAC BET degrader that tether HJB97 to a ligand for the E3 ubiquitin ligase VHL.

BF 227 is a candidate for an amyloid imaging probe for PET, with a Ki of 4.3 nM for Aβ1-42 fibrils.

BF 844 (BioFocus 844) is a small molecules capable of stabilizing mutant USH3 mutation CLRN1(N48K).

BF-168, a candidate probe for PET, is found to specifically recognize both neuritic and diffuse plaques, with a Ki of 6.4 nM for Aβ1-42.

BF738735 is a novel, broad-spectrum inhibitor of enterovirus replication (EC50=4-71 nM) that specifically targets host cell factor PI4KIIIβ with IC50 of 5.7 nM, 300-fold less potent for PI4KIIIα (IC50=1.7 uM).

BGB-3111 is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor.

BGC20-1531 (PGN-1531, AP 1531) is a potent, selective prostanoid EP receptor EP antagonist, exhibits high affinity at recombinant human EP4 receptors expressed in cell lines (pKB=7.6) and native EP4 receptors in human cerebral and meningeal artery (pKB=7.

BGG463 can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with a 50% inhibitory concentration (IC50) of 0.25 μM, 0.09 μM and 0.590 μM, respectively.

BHC (Myosin inhibitor BHC) is a small-molecule screen of skeletal muscle myosin inhibitor that suppresses movements without affecting membrane currents.

BHPI is a potent, noncompetitive small molecule ERα inhibitor (biomodulator) that selectively blocks proliferation of drug-resistant ERα-positive breast and ovarian cancer cells.

B-HT 920(Talipexole 2Hcl) is a dopamine D2 receptor agonist, α2-adrenoceptor agonist and 5-HT3 receptor antagonist, which displays antiParkinsonian activity.

BI 1467335 (PXS-4728A, PXS-4728) is a potent, selective, orally active SSAO/VAP-1 (AOC3) inhibitor with IC50 of 5 nM; displays >500-fold selective for VAP-1/SSAO over all the related human amine oxidases; diminishes leukocyte rolling and adherence induced by CXCL1/KC, also inhibits the migration of neutrophils to the lungs in response to LPS, Klebsiella pneumoniae lung infection and CLP induced sepsis.

BI 167107 is a highly potent agonist of the β2 adrenergic receptor (β2AR) and β1AR (IC50=3.2 nM) and shows some activity as α1A antagonist (IC50 = 32 nM).

BI 187004 (VTP-34072) is a novel potent, selective 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) inhibitor intended to treat type 2 diabetes mellitus (T2D)..

BI 207524 is a potent inhibitor of HCV thumb pocket 1 NS5B inhibitor with IC50 of 84 nM, inhibits Gt 1a/1b replicons with EC50 of 29/11 nM..

BI 665915 is a highly potent, selective, orally active 5-lipoxygenase-activating protein (FLAP) inhibitor with binding IC50 of 1.7 nM.

BI 671800 is a potent, oral prostaglandin D2 receptor (CRTH2) antagonist for treatment of asthma..

BI 6901 is a potent, selective CCR10 antagonist with Aequorin Ca2+ flux pIC50 of 9.0, shows high selectivity over other GPCRs.

BI 7189 is a highly selective bromodomains of BRD9 and BRD7 inhibitor with IC50<50 nM for BRD9, displays >1,000 fold selectivity over the bromodomains of BRD4.

BI 7271 is a highly selective bromodomains of BRD9 and BRD7 inhibitor with IC50<50 nM for BRD9.

BI 831266 is a potent, selective inhibitor of Aurora kinase B (AURKB) with IC50 of binding IC50 of 42 nM.

BI 885578 (BI-885578, BI885578) is a potent,selective, ATP-competitive IGF1R/InsR tyrosine kinase inhibitor with Kd of 9 nM/12 nM, IC50 of 1 nM/1 nM, respectively.

BI 894999 is a novel potent, selective BET inhibitor with IC50 of 5 and 41 nM for BRD4-BD1 and BRD4-BD2 bromodomains, respectively.

BI01383298 (BI-01383298) is a potent, specific sodium-citrate co-transporter SLC13A5 (NaCT, INDY), highly selective over other family members and other transporters..

BI-0314 (BI0314) is an allosteric activator of protein tyrosine phosphatase non-receptor type 5 (PTPN5, STEP) with potency of 56% at 500 uM, displays no activity against hPTP1B and hTCPTP.

BI1002494 (BI-1002494) is a novel, potent, and selective spleen tyrosine kinase (SYK) inhibitor with enzyme IC50 of 30 nM, cell IC50 of 7 nM (FcεR1-mediated histamine release in human monocyte-derived mast cells, in the presence of 0.1% albumin).

BI 135585 (BI-135585, BI135585) is a potent, selective, orally active 11β-HSD1 inhibitor with IC50 of 4.3 nM and 53 nM in human adipocytes and primary human adipose tissue, respectively.

BI-1388 is a potent, specific, macrocyclic inhibitor of HCV NS3 protease, inhibits viral replication for various HCV genotypes and for resistant mutants D168V and R155K.

BI-1935 is a potent, selective small molecule inhibitor of soluble epoxide hydrolase (sEH) with IC50 of 7 nM.

BI-1950 is a potent, selective LFA-1 antagonist that inhibits the binding of LFA-1 to ICAM-1 with Kd value of 9 nM.

BI-2545 is a novel potent, selective, orally available Autotaxin inhibitor with IC50 of 2.1 and 3.4 nM for huamn and rat ATX, respectively.

BI-3663 (BI 3663) is a cereblon-based degrader (PROTAC) of Focal adhesion tyrosine kinase (PTK2/FAK) with a median DC50 of 30 nM to >80% across a panel of eleven HCC cell lines.

BI-3802 (BI3802) is a highly potent and efficacious BCL6 degrader that potently inhibits the interaction of the BTB/POZ domain of BCL6 with several co-repressors in vitro with IC50 of <3 nM.

BI-4394 is a highly potent, selective MMP-13 inhibitor with IC50 of 1 nM, displays >1,000 fold selectivity against nine other MMP isoforms (MMP2/14, IC50=18/8.3 uM).

BI605906 is a potent, specific IKKβ inhibitor with IC50 of 380 nM (0.1 mM ATP), does not suppress signaling downstream of mTOR or activate AMPK.

BI8622 (BI-8622) is a specific small molecule inhibitor of the HUWE1 ubiquitin ligase with IC50 of 3.1 uM, does not inhibit the activity of other HECT-domain ubiquitin ligases (HECW2, NEDD4,UBA1 and UbcH5b).

BI8626 (BI-8626) is a specific, small molecule inhibitor of the HUWE1 ubiquitin ligase with IC50 of 0.9 uM, does not inhibit the activity of other HECT-domain ubiquitin ligases (HECW2, NEDD4,UBA1 and UbcH5b, IC50>50 uM).